Patients with confirmed PCa may also undergo focal therapy, which was a treatment modality for eliminating local cancer tissue, including high-intensity focused ultrasound, cryotherapy, focal laser ablation, and vascular-targeted photodynamic therapy, etc.; previous studies found focal therapy had specific effects on PSA reduction, failure-free survival, recurrence-free survival, and progression-free survival, but whether it could improve CSM and OM remained inconclusive [18, 28]. The gene discussed is KLK3; the disease is ocular melanoma.